Palonosetron 0,25 Teva 0,25 mg Solution for injection;
PDF Leaflet Revision Date: 23 February 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Prevention of acute nausea and vomiting from chemotherapy.
Dosage (summary)
0.25 mg IV bolus 30 mins before chemotherapy.
Onset of Action / Duration
Onset: 30 mins, Duration: Not specified
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Not recommended in pregnancy; discontinue breastfeeding during therapy.
Key Drug Interactions
- CYP2D6 inducers/inhibitors
- Serotonergic medications
- Corticosteroids
Contraindications
- Hypersensitivity to palonosetron or excipients
Common side effects
- Headache
- Constipation
Counselling Points
- Monitor for constipation
- Caution when driving or operating machinery
- Report any adverse reactions
Serious warnings
- Risk of serotonin syndrome
- Monitor for myocardial ischemia
- QT prolongation caution
Important Disclaimer
The Palonosetron 0,25 Teva 0,25 mg Solution for injection; professional information leaflet below is the property of Teva Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
